(Q41514384)

English

Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study

scientific article published on 28 January 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 October 2017

Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study (English)

1 reference

Europe PubMed Central

2 October 2017

radiation therapy

0 references

0 references

advanced head and neck cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

head and neck carcinoma

1 reference

based on heuristic

inferred from title

author name string

Jens Bentzen

1

1 reference

Europe PubMed Central

2 October 2017

Kasper Toustrup

2

1 reference

Europe PubMed Central

2 October 2017

Jesper Grau Eriksen

3

1 reference

Europe PubMed Central

2 October 2017

Hanne Primdahl

4

1 reference

Europe PubMed Central

2 October 2017

Lisbeth Juhler Andersen

5

1 reference

Europe PubMed Central

2 October 2017

Jens Overgaard

6

1 reference

Europe PubMed Central

2 October 2017

publication date

28 January 2015

1 reference

Europe PubMed Central

2 October 2017

Acta Oncologica

1 reference

Europe PubMed Central

2 October 2017

54

1 reference

Europe PubMed Central

2 October 2017

7

1 reference

Europe PubMed Central

2 October 2017

1001-1007

1 reference

Europe PubMed Central

2 October 2017

Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Factors associated with acute and late dysphagia in the DAHANCA 6 & 7 randomized trial with accelerated radiotherapy for head and neck cancer

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Evaluation of early and late toxicities in chemoradiation trials.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Human papillomavirus and survival of patients with oropharyngeal cancer.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14).

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Hypopharyngeal dose is associated with severe late toxicity in locally advanced head-and-neck cancer: an RTOG analysis

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Enteral feeding tubes in patients undergoing definitive chemoradiation therapy for head-and-neck cancer: a critical review

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2014.992547

21 January 2018

Identifiers

10.3109/0284186X.2014.992547

1 reference

Europe PubMed Central

2 October 2017

1 reference

Europe PubMed Central

2 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41514384&oldid=2105309268"